Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Biol Blood Marrow Transplant ; 18(2): 241-9, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-21791194

RESUMEN

We evaluated the safety and efficacy of plerixafor, subsequent to disease-specific chemotherapy followed by granulocyte-colony stimulating factor (G-CSF), in 37 multiple myeloma (MM) or lymphoma patients, who were candidates for autologous stem cell transplantation (ASCT) predicted as poor mobilizers (PMs). Patients were identified as predicted PMs according to the history of a previously failed mobilization attempt or the presence of ≥1 factors predicting an unsuccessful harvest, such as advanced disease, prior extensive radiotherapy, or prolonged treatment, with stem cell poisons, advanced age, or extensive bone marrow involvement. Plerixafor (0.24 mg/kg) was administered subcutaneously for up to 3 consecutive days while continuing G-CSF for 9 to 11 hours before the planned apheresis. Plerixafor administration was safe and no significant adverse events were recorded. We observed a median 4-fold increase (range: 1.4-32) in the number of circulating CD34(+) cells following plerixafor compared with baseline CD34(+) cell concentration (from a median of 5 cells/µL, range: 1-32, to a median of 32 cells/µL, range: 6-201). Twenty-seven of the 37 patients (14 of 17 with MM and 13 of 20 with lymphoma) had ≥2×10(6) CD34(+) cells/kg collected in 1-3 apheretic procedures. Of the 27 patients rescued with plerixafor, 24 (13 MM, 11 lymphoma) have been transplanted with plerixafor-mobilized peripheral blood stem cells, showing a rapid and durable hematologic recovery. Our results suggest that the addition of plerixafor to G-CSF after disease-oriented chemotherapy is safe and allows for a satisfactory harvest in order to perform a safe ASCT, in a relevant proportion of lymphoma and MM patients considered to be PMs.


Asunto(s)
Fármacos Anti-VIH/administración & dosificación , Factor Estimulante de Colonias de Granulocitos/administración & dosificación , Movilización de Célula Madre Hematopoyética , Células Madre Hematopoyéticas , Compuestos Heterocíclicos/administración & dosificación , Linfoma/terapia , Mieloma Múltiple/terapia , Trasplante de Células Madre de Sangre Periférica , Adulto , Anciano , Fármacos Anti-VIH/efectos adversos , Antígenos CD34/sangre , Bencilaminas , Ciclamas , Femenino , Factor Estimulante de Colonias de Granulocitos/efectos adversos , Compuestos Heterocíclicos/efectos adversos , Humanos , Linfoma/sangre , Masculino , Persona de Mediana Edad , Mieloma Múltiple/sangre , Recuperación de la Función , Trasplante Autólogo
2.
Bone Marrow Transplant ; 53(4): 461-473, 2018 04.
Artículo en Inglés | MEDLINE | ID: mdl-29330395

RESUMEN

Predicting mobilization failure before it starts may enable patient-tailored strategies. Although consensus criteria for predicted PM (pPM) are available, their predictive performance has never been measured on real data. We retrospectively collected and analyzed 1318 mobilization procedures performed for MM and lymphoma patients in the plerixafor era. In our sample, 180/1318 (13.7%) were PM. The score resulting from published pPM criteria had sufficient performance for predicting PM, as measured by AUC (0.67, 95%CI: 0.63-0.72). We developed a new prediction model from multivariate analysis whose score (pPM-score) resulted in better AUC (0.80, 95%CI: 0.76-0.84, p < 0001). pPM-score included as risk factors: increasing age, diagnosis of NHL, positive bone marrow biopsy or cytopenias before mobilization, previous mobilization failure, priming strategy with G-CSF alone, or without upfront plerixafor. A simplified version of pPM-score was categorized using a cut-off to maximize positive likelihood ratio (15.7, 95%CI: 9.9-24.8); specificity was 98% (95%CI: 97-98.7%), sensitivity 31.7% (95%CI: 24.9-39%); positive predictive value in our sample was 71.3% (95%CI: 60-80.8%). Simplified pPM-score can "rule in" patients at very high risk for PM before starting mobilization, allowing changes in clinical management, such as choice of alternative priming strategies, to avoid highly likely mobilization failure.


Asunto(s)
Movilización de Célula Madre Hematopoyética/normas , Selección de Paciente , Valor Predictivo de las Pruebas , Adolescente , Adulto , Anciano , Área Bajo la Curva , Niño , Preescolar , Femenino , Movilización de Célula Madre Hematopoyética/métodos , Humanos , Masculino , Persona de Mediana Edad , Mieloma Múltiple/terapia , Estudios Retrospectivos , Factores de Riesgo , Adulto Joven
3.
Biosystems ; 67(1-3): 27-34, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12459281

RESUMEN

The input-output behaviour of the Wiener neuronal model subject to alternating input is studied under the assumption that the effect of such an input is to make the drift itself of an alternating type. Firing densities and related statistics are obtained via simulations of the sample-paths of the process in the following three cases: the drift changes occur during random periods characterised by (i) exponential distribution, (ii) Erlang distribution with a preassigned shape parameter, and (iii) deterministic distribution. The obtained results are compared with those holding for the Wiener neuronal model subject to sinusoidal input.


Asunto(s)
Modelos Neurológicos , Neuronas/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA